Fontan Outcomes in Oligemia vs Plethora in Univentricular CHD
Summary
NIH registered a prospective cohort study (NCT07535203) comparing Fontan procedure outcomes in patients with cyanotic congenital heart disease classified by pulmonary blood flow characteristics. Fifty-two patients will be divided into oligemia and plethora groups and followed for approximately 1.5 years post-procedure to assess mortality, morbidity, pulmonary hemodynamics, functional capacity, neurocognitive status, and quality of life.
What changed
NIH added a new clinical trial registration for an observational study comparing outcomes between pulmonary oligemia and pulmonary plethora in patients with univentricular heart physiology undergoing the Fontan procedure. The study will enroll 52 participants and track outcomes including mortality, morbidity, pulmonary hemodynamics, functional capacity, neurocognitive status, and quality of life over approximately 1.5 years of follow-up.
Healthcare institutions conducting congenital heart disease research should note this study's focus on stratifying Fontan patients by pulmonary blood flow patterns. The study may inform future clinical decision-making regarding patient selection and risk stratification for staged palliation procedures. Patients enrolled in Fontan-related studies should discuss participation eligibility with their cardiac care teams.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Fontan Outcomes in Oligemia vs Plethora in Univentricular CHD
Observational NCT07535203 Kind: OBSERVATIONAL Apr 17, 2026
Abstract
This prospective cohort study evaluates differences in clinical outcomes between pulmonary oligemia and pulmonary plethora in patients with cyanotic congenital heart disease and univentricular heart physiology undergoing staged palliation culminating in the Fontan procedure.Fifty-two patients will be classified into two groups based on pulmonary blood flow characteristics and followed for approximately 1.5 years after the Fontan procedure. Outcomes include mortality, morbidity, pulmonary hemodynamics, functional capacity, neurocognitive status, and quality of life.
Conditions: Congenital Heart Disease (CHD), Univentricular Heart
Interventions: Fontan Procedure
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.